The future of lupus therapy modulating autoantigen recognition

The mainstay of the current treatment for systemic lupus erythematosus consists of steroids and immunosuppressants. However, these non-specific immunosuppressive therapies can cause infection and other serious adverse events. The regulation of the autoantigen-specific immune response is a promising...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2010-10, Vol.19 (12), p.1474-1481
Main Authors: Okamoto, A., Fujio, K., Yamamoto, K.
Format: Article
Language:English
Subjects:
Animals
Antigens
Autoantigens - immunology
Autoimmune diseases
Cloning
Disease
Genes
Genetic Therapy - methods
Humans
Immunologic Factors - therapeutic use
Immunotherapy
Lupus
Lupus Erythematosus, Systemic - immunology
Lupus Erythematosus, Systemic - therapy
Lymphocytes
Pathogenesis
Patients
Remission (Medicine)
Rheumatoid arthritis
Rheumatology
Steroids
T-Lymphocytes - immunology
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mainstay of the current treatment for systemic lupus erythematosus consists of steroids and immunosuppressants. However, these non-specific immunosuppressive therapies can cause infection and other serious adverse events. The regulation of the autoantigen-specific immune response is a promising therapeutic approach with maximal efficacy and minimal adverse effects. T cells are essential components of antigen-specificity in the immune system. At present, we do not have a sufficient strategy for manipulating the responses of antigen-specific T cells. In this review, we describe the efficacy of two therapeutic approaches involving the modulation of autoantigen recognition by T cells in lupus model mice: (1) therapy involving engineered autoantigen-specific regulatory T cells generated by the gene transfer of autoantigen-specific TCR genes and appropriate regulatory genes into self lymphocytes; (2) therapy involving selective depletion of autoantigen presenting phagocytes. These selective immunosuppressive approaches could be useful strategies for the treatment of systemic lupus erythematosus.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203310374306